(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 8.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Bio Techne's revenue in 2026 is $1,215,039,000.On average, 16 Wall Street analysts forecast TECH's revenue for 2027 to be $202,765,981,734, with the lowest TECH revenue forecast at $192,102,341,550, and the highest TECH revenue forecast at $212,488,712,490. On average, 12 Wall Street analysts forecast TECH's revenue for 2028 to be $222,681,897,960, with the lowest TECH revenue forecast at $206,843,255,922, and the highest TECH revenue forecast at $246,831,906,612.
In 2029, TECH is forecast to generate $242,440,995,948 in revenue, with the lowest revenue forecast at $224,093,262,102 and the highest revenue forecast at $259,691,002,128.